Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial

Por Pogue-Geile, Katherine L., Song, Nan, Jeong, Jong-Hyeon, Gavin, Patrick G., Kim, Seong-Rim, Blackmon, Nicole L., Finnigan, Melanie, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P., Swain, Sandra M., Wickerham, D. Lawrence, Geyer, Charles E., Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung
Publicado no J Clin Oncol (2015)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Por Perez, Edith A., Press, Michael F., Dueck, Amylou C., Jenkins, Robert B., Kim, Chungyeul, Chen, Beiyun, Villalobos, Ivonne, Paik, Soonmyung, Buyse, Marc, Wiktor, Anne E., Meyer, Reid, Finnigan, Melanie, Zujewski, JoAnne, Shing, Mona, Stern, Howard M., Lingle, Wilma L., Reinholz, Monica M., Slamon, Dennis J.
Publicado em 2013

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Tria...

Por Gavin, Patrick G., Song, Nan, Kim, S. Rim, Lipchik, Corey, Johnson, Nicole L., Bandos, Hanna, Finnigan, Melanie, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P., Swain, Sandra M., Wickerham, D. Lawrence, Geyer, Charles E., Jeong, Jong-Hyeon, Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung, Pogue-Geile, Kay L.
Publicado no JAMA Oncol (2017)